UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Resistance to targeted therapy in renal-cell carcinoma

The lancet oncology, 2009-10, Vol.10 (10), p.992-1000

2009

Volltextzugriff (PDF)

YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells

Developmental cell, 2019-05, Vol.49 (3), p.425-443.e9

2019

Volltextzugriff (PDF)

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

Journal of clinical oncology, 2009-12, Vol.27 (34), p.5794-5799

2009

Volltextzugriff (PDF)

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

Cancer immunology research, 2015-10, Vol.3 (10), p.1158-1164

2015

Volltextzugriff (PDF)

Arginase-producing myeloid suppressor cells in renal cell carcinoma patients : A mechanism of tumor evasion

Cancer research (Chicago, Ill.), 2005-04, Vol.65 (8), p.3044-3048

2005

Volltextzugriff (PDF)

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

Journal of clinical oncology, 2004-03, Vol.22 (5), p.909-918

2004

Volltextzugriff (PDF)

Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer

Clinical cancer research, 2015-04, Vol.21 (8), p.1925-1934

2015

Volltextzugriff (PDF)

BRAF Mutations in Metanephric Adenoma of the Kidney

European urology, 2012-11, Vol.62 (5), p.917-922

2012

Volltextzugriff (PDF)

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Journal of clinical oncology, 2021-03, Vol.39 (9), p.1029-1039

2021

Volltextzugriff (PDF)

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

Journal of clinical oncology, 2021-03, Vol.39 (9), p.1020-1028

2021

Volltextzugriff (PDF)

Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma

Clinical cancer research, 2004-09, Vol.10 (18), p.6342S-6346s

2004

Volltextzugriff (PDF)

Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy

Journal of immunotherapy (1997), 2005-09, Vol.28 (5), p.488-495

2005

Volltextzugriff (PDF)

Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors

Journal of clinical oncology, 2020-09, Vol.38 (27), p.3088-3094

2020

Volltextzugriff (PDF)

Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)

Urologic oncology, 2013-11, Vol.31 (8), p.1788-1793

2013

Volltextzugriff (PDF)

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)

Journal of clinical oncology, 2015-07, Vol.33 (21), p.2384-2391

2015

Volltextzugriff (PDF)

Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma

Clinical cancer research, 2021-03, Vol.27 (5), p.1371-1380

2021

Volltextzugriff (PDF)

Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma

Clinical cancer research, 2022-09, Vol.28 (18), p.4045-4055

2022

Volltextzugriff (PDF)

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial

JAMA oncology, 2017-09, Vol.3 (9), p.1249

2017

Volltextzugriff (PDF)

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Clinical cancer research, 2021-12, Vol.27 (24), p.6687-6695

2021

Volltextzugriff (PDF)

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3

The oncologist (Dayton, Ohio), 2023-03, Vol.28 (3), p.e167-e170

2023

Volltextzugriff (PDF)

Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial

The oncologist (Dayton, Ohio), 2024-03, Vol.29 (3), p.254-262

2024

Volltextzugriff (PDF)

Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings

Radiology, 2009-03, Vol.250 (3), p.793-802

2009

Volltextzugriff (PDF)

Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study

Journal of clinical oncology, 2015-10, Vol.33 (30), p.3431-3438

2015

Volltextzugriff (PDF)

High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma

Journal of translational medicine, 2011-12, Vol.9 (1), p.220-220, Article 220

2011

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Aktive Filter

KollektionAUTh Library subscriptions: Taylor & Francis Journals

ThemaImmunotherapy

ThemaKidney Neoplasms - Pathology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(42)

Sprache

Englisch
(42)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Humans
(41)
Life Sciences & Biomedicine
(40)
Science & Technology
(40)
Carcinoma, Renal Cell - Pathology
(31)
Oncology
(29)
Female
(25)
Male
(24)
Kidney Neoplasms - Drug Therapy
(23)
Middle Aged
(23)
Aged
(22)
Carcinoma, Renal Cell - Drug Therapy
(22)
Adult
(14)
Biological And Medical Sciences
(12)
Medical Sciences
(12)
Prognosis
(11)
Aged, 80 And Over
(10)
Nephrology. Urinary Tract Diseases
(10)
Treatment Outcome
(10)
Urology & Nephrology
(9)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Resistance to targeted therapy in renal-cell carcinoma

YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

Arginase-producing myeloid suppressor cells in renal cell carcinoma patients : A mechanism of tumor evasion

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer

BRAF Mutations in Metanephric Adenoma of the Kidney

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma

Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy

Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors

Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma

Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma

Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3

Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial

Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings

Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study

High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma

Aktive Filter

Suchergebnisse filtern